Recursion 1Q Earnings Recap with CEO and President Najat Khan

“What’s the one question we obsess over at Recursion? ‘How do we harness the full power of AI to consistently and with urgency create better medicines for patients’?” In a recap of Recursion’s recent 1Q earnings, CEO and President @Najat Khan talks about the tangible evidence that Recursion’s AI platform is delivering. They include: ▪️ REC-1245, a potential first-in-class oncology program where both the biology and molecule were discovered using the Recursion OS. Early clinical data shows a well-tolerated profile with no dose-limiting toxicities and an encouraging PK profile, with more data expected in the second half of this year. ▪️ REC-4881, a potential first-in-disease program for the rare disease FAP that has already shown strong proof of concept with meaningful and durable impact. We’ve now initiated engagement with the FDA on a potential path to registration, with an update expected in the second half of this year. ▪️ REC-4539, a potentially best-in-class LSD1 inhibitor for small cell lung cancer and AML in which the first patient was recently dosed in the Phase 1 trial. “This is a precision-designed molecule,” Najat says, “built to address class-limiting toxicity” with the potential for “improved safety and CNS penetration.” It’s not about one asset, Najat says, but building a “repeatable, AI-driven product engine that’s starting to deliver across discovery and into the clinic.” Read Recursion’s full earnings report here: https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides #earnings #recursion #investor #AI #drugdiscovery #techbio